| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 72.59 | 11.5% |
| Total Income | 73.49 | 11.5% |
| Expenditure | 61.02 | 7.6% |
| PBT | 12.47 | 35.4% |
| Net Profit | 9.18 | 27.9% |
| OPM | 32.72% | 3.24pp |
| NPM | 12.48% | 1.60pp |
| EPS | 1.80 | 26.8% |
Suraksha Diagnostic Reports 18.83% Y-o-Y Increase in Total Income for Q1 FY26
08 Aug 2025 · 8 Aug 2025, 08:12 pm
Summary
Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter ended 30 June 2025, with Total Income for Q1 FY26 increasing by 18.83% year-on-year.
Key Highlights
- 1
Total Income for Q1 FY26 increased by 18.83% year-on-year
- 2
Q1 FY26 EBITDA grew by 13.51% year-on-year
- 3
Profit After Tax (PAT) for Q1 FY26 grew by 19.67% year-on-year
- 4
Launched Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services
- 5
Acquired 63% stake in Fetomat Wellness Private Limited
- 6
Expanded footprint with addition of three new centres in the quarter
Management Comments
Ms Ritu Mittal
Joint Managing Director & CEO
We are pleased to report a strong performance for Q1 FY26, driven by consistent growth across our operations... We remain committed to innovation, operational excellence, and sustainable growth as we advance our mission to redefine healthcare delivery through genomics.
Informational and educational content only. Not investment advice.